Introduction
The concept of precision cancer prevention is inherently reliant on devising accurate and individualized risk assessment. Germline mutations in highly penetrant cancer susceptibility genes (e.g., BRCA1 and BRCA2, DNA mismatch repair [MMR] genes, APC, TP53, etc.) are thought to underlie a substantial fraction of all malignancies, and carriers of such mutations are ideal candidates in whom to develop and implement precision prevention. Multigene panel testing has identified families affected by unexpected mutations in high-penetrance genes (e.g., colon cancer patients with BRCA1 and BRCA2 mutations and breast cancer patients with Lynch syndrome), suggesting that the spectrum of cancer risk conferred by such germline mutations is much wider and more complicated than anticipated (Yurgelun et al., 2017) . Furthermore, even for individuals known to have inherited cancer susceptibility, contemporary prevention strategies often rely on the assumption that all carriers are at uniformly high cancer risks, resulting in many healthy mutation carriers being recommended to undergo prophylactic radical risk-reducing surgery. Advancing the field of cancer prevention for individuals with particular germline mutations will thus require a more advanced understanding of the lifestyle, environmental, and other factors (including germline variants) that influence risk of specific malignancies and of novel, precise interventions for reducing cancer risk.
Understanding the Spectrum, Magnitude, and Modifiers of Hereditary Cancer Risks
The two most common high-penetrance inherited cancer syndromes are hereditary breast and ovarian cancer (caused by germline mutations in BRCA1 or BRCA2, associated with homologous recombination and other types of DNA repair) and Lynch syndrome (caused by germline mutations in the MMR gene family, primarily MLH1, MSH2, MSH6, or PMS2) . These and other hereditary cancer syndromes are characterized by high lifetime risks of particular component cancers (e.g., breast and ovarian cancer in BRCA1-and BRCA2-mutation carriers and colorectal and endometrial cancer in individuals with Lynch syndrome), which are typically used to aid in the clinical identification of families. The fundamental question of why certain germline mutations in cancer susceptibility genes with broad functions (e.g., DNA repair genes) predispose to a particular spectrum of malignancies, however, rather than generalized systemic cancer risk, remains. Studies of BRCA1 carriers are providing novel insights into the high penetrance for breast and ovarian cancer. For example, impaired ovarian hormone regulation and signaling in normal breast tissue from BRCA1 carriers may contribute to early stages of breast cancer development in this setting (Communal et al., 2016) .
Mouse models have begun to provide extensive insight into hereditary colorectal cancer syndromes by unraveling some of the key mechanisms of intestinal neoplastic transformation in these settings. One recent study in a mouse model of Lynch syndrome (MMR-deficient intestinal carcinogenesis) elegantly demonstrated that the short-chain fatty acid butyrate, generated by gut microbiota from dietary fibers and complex carbohydrates, can act as an oncometabolite by promoting the proliferation of cancer-initiated intestinal epithelial cells (Belcheva et al., 2014) . Interestingly, butyrate can have differential functions in the colon, including as a tumor-suppressive metabolite, referred to as the butyrate paradox, which is poorly understood but may in part reflect the host's genetic background. Either alterations to the gut microbiome or reductions in dietary carbohydrate intake markedly reduce transformation in MMR-deficient, but not MMR-proficient, mice. This study shows how nutrition and microbiota can contribute to colon polyp and cancer development and highlights the need to decipher the interplay between host genetics, microbes, diet, and oncogenesis (Belcheva et al., 2014) . Such mechanistic data are crucial for understanding why certain inherited forms of cancer risk predispose to a particular spectrum of cancers and suggest that there are extrinsic factors (antibiotic, diet, or microbial reprogramming), which could theoretically be exploited to facilitate cancer prevention. Building on this concept, another study demonstrated that celecoxib (a COX-2 inhibitor known to reduce intestinal adenoma burden) induces alterations in the gut microbiome and metabolome, reducing intestinal crypt stem cell proliferation and adenoma formation in APC Min/+ mice, a model of familial adenomatous polyposis (Montrose et al., 2016) . In particular, celecoxib therapy in this study was associated with increased gut Coriobacteriaceae, which was felt to suppress production of metabolites (e.g., glycine and serine) that are known to contribute to oncogenesis. Further research into the mechanisms of oncogenesis in various inherited conditions will most likely facilitate the identification of novel prevention targets, such as in individuals with Lynch syndrome, where aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have already demonstrated significant efficacy in reducing colorectal cancer risks. Beyond the question of why certain germline alterations confer risks of particular cancers and not others, the magnitude of risk associated with welldescribed cancer predisposition genes remains a matter of debate. Most cancer risk estimates associated with a given syndrome are derived from patients and families ascertained through classic clinical histories and are thus most likely prone to significant biases. Furthermore, these fail to account for other factors that may influence risk and penetrance estimates. For example, BRCA1 and BRCA2 mutations vary considerably between studies. In retrospective studies, the cumulative breast cancer risk estimates to age 70 ranges from 40%-87% and 27%-84% for BRCA1-and BRCA2-mutation carriers, respectively. For ovarian cancer risk, the ranges are from 16%-68% and 11%-27% for BRCA1-and BRCA2-mutation carriers, respectively (Milne and Antoniou, 2016) . The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and the prospective International BRCA1/2 Carrier Cohort Study (IBCCS) are large-scale, multicenter collaborative efforts focused on identifying the risks of breast, ovarian, and other cancers in BRCA-mutation carriers and assessing other risk modifiers. Most breast cancer susceptibility SNPs identified by such efforts are differentially associated with estrogen receptor (ER)-negative or -positive breast cancer in the general population and, correspondingly, in BRCA1-or BRCA2-mutation carriers, respectively. Similarly, only loci found to be associated with high-grade serous ovarian cancer in the general population (e.g., 19p13.11) modify risk of ovarian cancer in BRCA1-and BRCA2-mutation carriers, where tumors are predominantly of this subtype (Milne and Antoniou, 2016) .
Although, individually, the known cancer-risk-modifying SNPs confer only moderate increases, their effects can be combined into polygenic risk scores (PRSs), which are associated with considerable risks. The influence of PRSs on predicting cancer risk is particularly pronounced in high-risk individuals such as BRCA1-and BRCA2-mutation carriers given that even small relative risk modifications to their baseline elevated risk translate into large differences in their absolute cancer risk. For example, using a PRS of 94 breast-cancer-and 18 ovarian-cancer-modifying SNPs, CIMBA has shown that BRCA1-mutation carriers at the 90 th percentile of the PRS have an absolute risk of 75% of developing breast cancer by age 80, while those at the 10 th percentile have a risk of 56%. In BRCA2-mutation carriers, the ovarian cancer risk is 19% by age 80 for women at the 90 th percentile of the PRS compared with only 6% for those at the 10 th percentile (Kuchenbaecker et al., in press ). An immediate challenge is to extend the PRS studies to risk of prostate and breast cancer in male BRCA carriers and to validate the PRS in prospective studies. As with nuclear GWASs, certain inherited mitochondrial DNA alterations modify (lower) risks of breast cancer in germline BRCA2 mutations. Such studies will be important in determining how useful personalized risk prediction will be in altering the uptake or timing of prophylactic surgery and other clinical interventions. Whether a PRS alone would identify BRCA1-and BRCA2-mutation carriers with a sufficiently low enough risk of ovarian or breast cancer to obviate (or delay) the need for risk-reducing surgery is unclear. Ideally, personalized prediction in BRCA1-and BRCA2-mutation carriers will also include information on reproductive and family history, mammographic density, lifestyle, and environmental factors, and the position of the mutation within a breast, prostate, or ovarian cancer cluster region-all validated and implemented through developments in comprehensive risk prediction models, at which point personalized risk prediction will likely have much greater clinical utility (Kuchenbaecker et al., in press; Milne and Antoniou, 2016) . Another critical potential payoff from cancer risk SNPs, such as those identified by genome-wide association studies (GWASs), will be their ability to identify novel cancer genes and/or pathways (through functional follow-up studies) underlying the observed risk, which could be exploited for future drug development or repositioning for cancer prevention, possibly aided by modeling in BRCAmutant mouse, organoid, zebrafish, and other relevant model systems. Notably, SNPs have only small effects on cancer risk, although this risk effect size is not necessarily related to other outcomes or druggability of a target. GWASs do not themselves identify the genes targeted by the associated SNPs. Fine mapping, in silico predictions, and in vitro, or even in vivo, functional analyses in follow-up studies are needed to establish this link. A comprehensive analysis of the genetic evidence predicting drug mechanisms suggested that selecting drug targets with genetic support from either rare, high-penetrance Mendelian diseases or GWASs of common complex diseases could double the success rates in clinical trials (Nelson et al., 2015) . GWAS data first revealed the importance of the 1p31.3 locus, which brought attention to the IL-23/IL-17 axis and ultimately led to development of several FDA-approved psoriasis drugs targeting IL-17, which is a pathway that is of increasing interest in the development of colorectal and other cancers (Spira et al., 2016) . For BRCAassociated breast cancer, proof of principle for this concept is provided by the finding that SNPs at 6q25 are associated with risk of ER-negative and -positive disease in both BRCA1-mutation carriers and the general population and affect the expression of ESR1, the target of tamoxifen (Dunning et al., 2016) , and thus may enhance the chemopreventive effects of tamoxifen in these settings. SNPs for novel drug repositioning in prevention could include those at 6p23, a GWAS-identified locus (Michailidou et al., 2013) particularly associated with breast cancer risk in BRCA2 carriers, given that it is located near SIRT5, which is thought to be a target of histone deacetylase inhibitors such as panobinostat, which was recently FDA approved for multiple myeloma.
Precision Cancer Prevention in Inherited Cancer Risk
Most current evidence-based strategies for managing patients with known inherited risks of cancer rely on relatively crude forms of cancer prevention, such as prophylactic surgeries (e.g., hysterectomy and removal of the fallopian tubes and ovaries [salpingo-oophorectomy] in women with Lynch syndrome and salpingo-oophorectomy and mastectomy in women with BRCA1 and BRCA2 mutations). While mostly effective at reducing both cancer risk and mortality, they confer significant long-term morbidity such as surgical menopause, which can both limit patient uptake (especially early in life, when their potential preventive impact is inherently greatest) and often generate their own medical and psychological sequelae. Risk-reducing salpingo-oophorectomy has been a cornerstone of breast cancer prevention in BRCA1-and BRCA2-mutation carriers for decades. However, recent analyses suggest that this is not as effective for premenopausal BRCA1-mutation carriers (Kotsopoulos et al., 2016) , and so there exists an unmet medical need for other approaches. Although most breast cancers arising in BRCA1-mutation carriers are tamoxifen-resistant and ER-negative, tamoxifen does reduce contralateral breast cancer in BRCA1 carriers, likely due to BRCA crosstalk and interactions with hormonal effects in early ontogeny or stromal estrogen signaling.
An exciting opportunity in precision prevention is emerging for BRCA1-mutation carriers based on studies of a highly proliferative subset of luminal progenitor cells that give rise to basal-like breast cancer. These cells constitutively express RANK (receptor activator of nuclear factor kappa-B [NF-kB]) and are hyper-responsive to RANK ligand (RANK-L). Interference of this pathway produces significant preventive activity in breast organoids and mouse models (Figure 1) . Furthermore, in a pilot study of six BRCA1 carriers, a fully human monoclonal antibody targeted against RANK-L that is FDA approved with a well-established safety record for treatment of osteoporosis (denosumab) inhibited RANK-positive BRCA1-mutated breast cancer progenitors, with promising effects on proliferation or clonogenic potential in breast tissue (Nolan et al., 2016) . There is some evidence that germline SNPs in RANK are associated with breast cancer risk in these carriers, but larger studies and demonstration that the SNPs have regulatory effects on RANK itself will be required to clarify the relevance of this finding. RANK-L inhibition in BRCA1-mutation carriers could thus prevent and/or delay tumor onset for premenopausal women given that RANK-L is a progesterone-responsive gene and risk-reducing salpingo-oophorectomy has limited efficacy in this setting (Kotsopoulos et al., 2016) , leaving mastectomy as the primary preventive approach. Such intriguing findings support the planned, international trial repurposing denosumab as a breast cancer prevention agent for BRCA1-mutation carriers and could include other BRCA1-associated cancers (e.g., ovarian and pancreatic) as secondary endpoints.
While not a classic component cancer of either syndrome, pancreatic cancer is notoriously lethal with essentially no , an international breast cancer prevention trial of denosumab is planned for BRCA1-mutation carriers (bottom). Abbreviations are as follows: RANK, receptor activator of nuclear factor kappa-B (NF-kB); RANK-L, RANK ligand; ER, estrogen receptor; PR, progesterone receptor; MaSC, mammary stem cell; NEMO, NF-kB essential modulator; ATM, ataxia telangiectasia mutated; IKKa, inhibitor of kappaB kinase alpha; PARP, poly (ADP-ribose) polymerase.
effective prevention, early detection, or therapy, representing an unequivocal unmet medical need. Emerging data indicate a very high (>15% in a clinic-based cohort) prevalence of germline mutations in cancer predisposition genes (most commonly BRCA1 and BRCA2, but also PALB2, the MMR genes, ATM, CDKN2A, TP53, and others) among otherwise unselected pancreatic cancer patients and even higher rates among Ashkenazi Jewish patients (Salo-Mullen et al., 2015) . Such data recently led to National Comprehensive Cancer Network (NCCN) updated guidelines now recommending germline BRCA1 and BRCA2 testing for all pancreatic cancer patients of Ashkenazi ancestry. Data further indicate, however, that classic high-risk features (e.g., young age at diagnosis or family history of cancer) have poor sensitivity for identifying even non-Ashkenazi pancreatic cancer patients likely to harbor such germline mutations, suggesting that performing multigene germline testing on all newly diagnosed pancreatic cancer may very well be the most effective approach for identifying high-risk families. The first real signal of benefit from early detection research (imaging people with high-penetrance mutations) was recently reported, adding to the enthusiasm for the changing pancreas guidelines for germline testing (Vasen et al., 2016) . Precedent for such a ''test everyone'' approach already exists in ovarian cancer, where NCCN guidelines recommend that all women with epithelial ovarian cancer (where screening has limited benefit) undergo germline analysis of BRCA1 and BRCA2 given that a substantial fraction of unselected women with ovarian cancer will carry such mutations, many of whom lack clinical histories suggestive of hereditary breast/ovarian cancer.
Utilization of such genetic screening approaches is likely to be critical to devising precision prevention efforts against particular forms of inherited cancer. Recent data in BRCA1-and BRCA2-related pancreatic cancer (Connor et al., 2016) identify somatic mutational patterns and molecular markers of increased antitumor immunity and tumor neoantigens, suggesting a role for immune-based mechanisms in treating and preventing such cancers. Furthermore, the profound ability of immune checkpoint blockade to successfully treat MMR-deficient cancers with widespread accumulation of somatic frameshift mutations, such as those seen in Lynch syndrome, has added to the enthusiasm for testing tumors for MMR-deficiency and microsatellite instability (MSI). Such universal tumor testing is standard practice for all newly diagnosed colorectal cancers and is becoming commonplace for all endometrial cancers so as to comprehensively screen these patients for Lynch syndrome. Given increasing interest in identifying patients who could benefit from immunotherapy, it is likely that such MMR-deficiency tumor testing will be expanded to other cancer types, which may lead to an increase in Lynch syndrome identification among individuals lacking classic component cancers. Furthermore, these breakthrough advances regarding the immune system's ability to treat and control MMR-deficient cancers have generated interest in the possibility of using immunebased strategies for cancer prevention, such as cancer vaccines, targeting predictable MSI-induced neoantigens in healthy Lynch syndrome carriers (Spira et al., 2016) .
Conclusion
The full potential for genetic medicine to facilitate cancer prevention can only be realized through a comprehensive understanding of the diversity, biology, and magnitude of risk conferred by given germline alterations and by the development and implementation of effective risk-reducing interventions. Major progress is being made in better understanding the phenomenon of inherited cancer risk, including advances in microbiome biology and immune oncology, which are providing tantalizing prevention leads. Other key advances include the growing ability to personalize cancer risk estimates for individuals with highly penetrant inherited syndromes by using genetic (e.g., PRS), lifestyle, and environmental factors. Furthermore, compelling studies of luminal progenitor cell biology in BRCA1-mutant models have led to a transformative precision medicine trial. Additional investigation into these groundbreaking areas holds the promise of moving the field beyond empiric, prophylactic surgical approaches to rationally designed personalized strategies for cancer prevention in individuals with inherited cancer risk. GWASs illustrate a relatively untapped treasure trove for discovering novel genes and/or pathways underlying cancer risk and immune function, with future possibilities of patient selection and stratification and, perhaps most importantly, drug development or repositioning. Future GWAS integrating nuclear and mitochondrial studies will provide a more full germline landscape, including somatic interactions. Leveraging these many promising advances toward personalized risk assessment and precision cancer prevention for individuals with inherited cancer risk will be crucial for ultimately attaining the goal of more widespread cancer prevention in the general population.
